An interventional study of High protein diet and Low protein diet in Metabolic Syndrome X and Weight Loss, sponsored by Mexican National Institute of Public Health. Completed at 1 site in Mexico. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-16.
Sponsored by Mexican National Institute of Public Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Metabolic Syndrome with a site in Mexico — 6 open to participants now, 7 under way, 1 of them phase 3. Metabolic Syndrome · Mexico.
Among the 41 studies in Metabolic Syndrome with a site in Mexico, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2014, is one of 20 with no phase, and was the 10th registered.
2,120 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →6 of the 41 studies in Metabolic Syndrome with a site in Mexico are open now. Recruiting first, the newest first:
University of Guadalajara · Sites in Mexico
Ages 18–60
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
University of Guadalajara · Sites in Mexico
Ages 30–60
Jaime Daniel Mondragon · Sites in Mexico
Ages 60–80
JULIO GRANADOS MONTIEL · Sites in Mexico
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 51 across the 36 interventional studies, 40 across the 5 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 41 have an industry lead sponsor. The 10 most frequent:
Mexican National Institute of Public Health is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Mexican National Institute of Public Health has 3 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Metabolic Syndrome with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
| NCT07567378JULIO GRANADOS MONTIELCARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Metabolic Syndrome with a site in Mexico, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomised clinical trial with a 6-month follow-up in Mexican adult men and women (20-65 years) with Metabolic Syndrome (MS). The sample size was calculated using a formula that compares two means, an alpha of 0.05 and a power of 95%. Based on these calculations, we established a baseline sample of 118 adults. For the diagnosis of MS, we used the classification from the International Diabetes Federation (IDF). 150 patients were screened; however, 32 were excluded because they did not meet the criteria. Doctors wrote down medical history; nutritionists conducted anthropometry (weight, height, and waist circumference); and nurses measured blood pressure and withdrew venous blood for determination of glucose, triglycerides, and HDL-cholesterol. After being randomly assigned to one of two groups, the control group received a diet with a lower protein content (0.8gr/kg body weight), and the intervention group received a diet with higher protein content (1.34gr/kg body weight). Both diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less.
For the intervention group, meal replacements were made with soy protein, and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Used as a substitute for food, the protein-enriched drinks were prepared with 250ml of either milk with 1.5% fat or just water. For both groups, the calorie density of the diet was adjusted for the baseline metabolic rate of each participant with a restriction of 500kcal/day.
Our study was a randomised clinical trial with a 6-month follow-up in Mexican adult men and women (20-65 years) with Metabolic Syndrome (MS). The individuals were invited to participate from posters and social network advertising. The study was conducted in two Mexican clinics (Mexico City and Cuernavaca) for obesity and metabolic disorders, used by the Mexican National Institute of Public Health (INSP) as recruitment centers. The sample size was calculated using a formula that compares two means, an alpha of 0.05 and a power of 95%. Based on these calculations, we established a baseline sample of 118 adults.
For the diagnosis of MS, we used the classification from the International Diabetes Federation (IDF), and therefore participants were required to have three or more of the following criteria: a) waist circumference ≥90 cm in men and ≥80 cm in women, b) triglycerides ≥150 mg/dL, c) high density lipoprotein (HDL-cholesterol) \<40 mg/dL in men and \<50 mg/dL in women, d) blood pressure ≥130/85 mmHg; and e) fasting glucose ≥100 mg/dL. Exclusion criteria included bariatric surgery for weight loss, smoking, use of alcohol or drugs, psychiatric disorders, anti-obesity medication, soy protein intolerance, women not using birth control methods, and not pregnant or lactating, and body weight gain or loss greater than two percent three months prior to the start of the study. To achieve the baseline sample of 118 adults, 150 patients were screened; however, 32 were excluded because they did not meet the criteria.
During screening, individuals interested in participating received an explanation of the study design and were given sufficient time to consider inclusion in the clinical trial and complete the form for informed consent. On the same day as consent, doctors wrote down medical history; nutritionists conducted anthropometry (weight, height, and waist circumference); and nurses measured blood pressure and withdrew venous blood for determination of glucose, triglycerides, and HDL-cholesterol.
After the medical evaluation and nutritional status, we provided meal replacements enriched with soy protein that were consumed during the following two days, testing soy protein tolerance. Each clinic supervisor enrolled participants, and the study coordinator conducted the randomization sequencing and assigned participants to interventions.
After being randomly assigned to one of two groups, the control group received a diet with a lower protein content (0.8gr/kg body weight), and the intervention group received a diet with higher protein content (1.34gr/kg body weight). Both diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR) based on the Harris-Benedict´s formula. The overall study design is shown in Figure 1.
For the intervention group, meal replacements (drinks and bars) were made with soy protein, and indivi-dualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily.
After randomization (week 0), participants received specific diet instructions. Each month, diets contained 15 different options and were sufficient to meet the needs of micronutrients recommended by the US Institute of Medicine (recommended dietary intake) according to age and sex.
In the intervention group, participants consumed two, protein-enriched drinks, contributing to the daily protein intake (1.34g protein/kg body weight) along with conventional foods and two low-fat bars. Used as a substitute for food, the protein-enriched drinks were prepared with 250ml of either milk with 1.5% fat or just water. The nutritional contents of the protein-enriched drink with milk contained 145 calories, 9g protein, 3g fat, and 20.5g carbohydrates. For water, the nutritional contents of the protein-enriched drink contained 22 calories, 5g protein, 0.2g fat, and 0g carbohydrates. In the control group, participants ate three meals and two snacks to have a daily intake of 0.8g protein/kg body weight. For both groups, the calorie density of the diet was adjusted for the baseline metabolic rate of each participant with a restriction of 500kcal/day.
Measurements Previously trained on standards for procedure, nutritionists completed monthly documentation of food frequency questionnaires for participants´ total caloric intake and grams of protein consumed per day. To minimize errors, the nutritionists and participants scrutinized and discussed the food diaries. The nutritionists also conducted anthropometry (weight and waist circumference) at baseline and at three and six months, using internationally recognized techniques.[14] The weight and body composition was measured by an Analyzer Avis 333, and the waist circumference was measured with a tape measure, using the line between the lower costal border and the iliac crest as reference points. At baseline, height was measured with a wall stadiometer (SECA Model 222) with an accuracy of 0.1cm. Body mass index (BMI) was calculated as weight/height 2.
Nurses measured blood pressure after 10 minutes of rest with a digital sphygmomanometer (OMRON HEM-907), following the recommendations of the American Heart Association. Blood samples were drawn after a 9- to 12-hour fasting and processed without delay. Laboratory testing included results for metabolic syndrome and HDL-cholesterol, insulin, hemoglobin A1c (HbA1c), C-reactive protein (CRP), direct bilirubin and indirect bilirubin. All measurements were performed at the Mexican National Institute of Public Health (INSP). A previously validated questionnaire was used to evaluate adherence to study recommendations for diet and exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
STATISTICAL ANALYSIS The results were shown for the baseline as mean ± standard deviation; and for the comparison between baseline to 6 months as absolute changes or percentage of weight loss. We used the analysis of variance (ANOVA) for means and X2 test for percentages to compare the two groups overtime. Two strategies were used to analyze the data: 1) all participants who completed the study after six months, and 2) those participants who dropped out of the study between baseline and six months, using the last recorded measure-ment.
The analysis of percentage of weight loss between baseline and 6 months we adjusted for adherence to study recommendations. For this analysis, only the participants who adhered to a minimum of 75% of the study design recommendations were considered. Statistical calculations were performed using the STATA program version 13.
Ethical and biosecurity This study was approved by the ethics, research, and biosafety committees from the INSP. Written informed consent was obtained from all participants. All researchers participated in an ethics certification course, "Human Participants Protection Education for Research Teams", given by the US National Institutes of Health (NIH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
Other: Low protein diet
HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
Other: High protein diet
Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
Also known as: Intervention group
Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
Also known as: Placebo comparator
Changes in body weight (weight loss)
Changes in body weight will be evaluate through measures in baseline (month 0), month 3 (intermediate) and month 6 (final) by an Body weight Analyzer (model Avis 333)
Time frame: Six months
The record gives a start of Jan 2014, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mexican National Institute of Public Health